Antiplatelet therapy for primary prevention in diabetes

Diabetes and Metabolism

Volumn 32, Issue HS2, 2006, Pages

  Ambrosi, P ^a   Villani, P ^a   Bouvenot, G ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

Aspirin; Clopidogrel; Diabetes mellitus; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; HIGH RISK POPULATION; HUMAN; CLINICAL TRIAL; DIABETIC ANGIOPATHY; PRIMARY PREVENTION; REVIEW;

ASPIRIN; CLINICAL TRIALS; CORONARY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION;

EID: 34248395574     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(06)70487-6     Document Type: Article

References (27)

1. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Br Med J 1994;308:81-106.
2. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2004;27:572-73.
3. Cull CA, Neil HA, Holman RR. Changing aspirin use in patients with type 2 diabetes in the UKPDS. Diabet Med 2004;21:1368-71.
4. Persell SD, Baker DW. Aspirin use among adults with diabetes. Arch Intern Med 2004;164:2492-9.
5. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
6. Ho JE, Paultre F, Mosca L. Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the women's pooling project. Stroke 2003;34:2812-6.
7. Chong DO, Aaron R, Folsom, et al. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004;109:855-60.
8. Juutilainen A, Lehto S, Ronemaa T, Pyorala K, Laakso M. Type 2 diabetes as a coronary risk equivalent. An 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005;28:2901-7.
9. Hu G, Jousilahti P, Qiao Q, Peltonen M, Katoh S, Tuomilehto J. The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease. J Am Coll Cardiol 2005;45:1413-8.
10. Wannamethee SG, Shaper AG, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart 2004;90:1398-403.
11. Vaccaro O, Lynn E, Eberly PH, et al. Impact of diabetes and previous myocardial infarction on long-term survival. Arch Intern Med 2004;164:1438-43.
12. Lotufo PA, Gaziano JM, Chae CU, et al. Diabetes and all-cause -and coronary heart disease mortality among US male physicians. Arch Intern Med 2001;161:242-7.
13. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women. 20 years follow-up. Arch Intern Med 2001;161:1717-23.
14. Evans J, Wang J, Morris A. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had a myocardial infarction : cross sectional and cohort studies. Br Med J 2002;324:1-5.
15. Eberly LE, Cohen JD, Prineas R, Yang L for the Multiple Risk Factor Intervention Trial Research Group. Impact of incident diabetes and incident cardiovascular disease on 18-year mortality. The Multiple Risk Factor Intervention Trial experience. Diabetes Care 2003;26:848-54.
16. Ariesen MJ, Claus SP, Rinkel JE, Algra A. Risk factors for intracerebral haemorrhage in the general population: a systematic review. Stroke 2003;34:2060-5.
17. Steering Committee of the Physicians' Health Study research group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35.
18. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
19. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low dose aspirin on patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
20. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-60.
21. The ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: early treatment diabetic retinopathy report. JAMA 1992;268:1292-300.
22. Sacco M, Pellegrini F, Roncaglia MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Results of the Primary Prevention Project trial. Diabetes Care 2003;26:3264-72.
23. Bhatt DL, Fox KAA, Hacke W, et al.; CHARISMA Investigators. Clopidogrel plus aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
24. Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)- its relation to metabolic control. Thromb Res 2004;113:101-13.
25. Evangelista V, Totani L, Rotondo S, et al. Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost 2005;93:8-16.
26. Angiolillo DJ, Fernadez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-5.
27. Albert SB, Hasnain BI, Ritter DG, Joist JH, Mooradian AD. Aspirin sensitivity of platelet aggregation in diabetes mellitus. Diabetes Res Clin Pract 2005;70:195-9.